MedTrace Logo

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT04282070 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2021-12-21

No results posted yet for this study

Summary

This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

SHR-1701

Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

DRUG

Gemcitabine

Maximum 6 cycles for combined therapy.

DRUG

Cisplatin

Maximum 6 cycles for combined therapy.

DRUG

Albumin Paclitaxel

Maximum 6 cycles for combined therapy.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-27
Primary Completion
2022-04-16
Completion
2022-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04282070 on ClinicalTrials.gov